ENDV - Endonovo Therapeutics Inc

From OTC Wiki
(Redirected from ENDV)
Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

OTC Market: OTCQB

Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis.

Jump to: Wiki | News | Links | FAQs | Opinions

Edit Wiki page
Become Wiki Editor
Learn to edit


ENDV Stock - Endonovo Therapeutics Inc
ENDV Stock - Endonovo Therapeutics Inc

Endonovo Therapeutics Inc (OTC: ENDV)


On October 12, 2021 the company issued a shareholder update stating, "As of July 2021, Endonovo has executed a Letter of Intent (LOI) to purchase its first highly profitable regional leader in the specialty construction industry (the Target)...Both parties expect to execute a definitive purchase agreement later this month and close by December 31, 2021. The Company is currently performing its due diligence on the Target."[1]


Create News


Wed, 14:08 November 30, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Thu, 14:07 November 17, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 14:08 November 7, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Tue, 17:52 September 27, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Thu, 13:08 July 28, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Thu, 15:31 July 21, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 13:09 April 25, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 13:09 April 11, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Endonovo Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |

More News: OTC Markets

ENDV Stock

As of 11/1/2022 there were 168,476,730 shares of ENDV stock outstanding.

As of 10/31/2022 short interest was 1,500 shares, which represents 1 day to cover.

Symbol change from ENDVD to ENDV on 1/21/2020.

Edit Links page

Create FAQs page


Crescendo | Posted on Mar 7, 2022 at 7:56 pm | Bear

Management failed miserably as a biotechnology company so now they are changing to a completely unrelated industry. If the acquisition occurs and is earning $5,000,000 as they say then how will the company pay for it? Dilution is the only real option and at the current share price and market cap the dilution will be astronomical. Moreover, the update regarding the acquisition is so vague as to make me wonder if it will every really happen. It could just be a ploy to pump up the stock price for a few months.

Otiswick66 | Posted on Mar 7, 2022 at 7:55 pm | Bull

If the stated acquistion occurs as planned, and they continue with this new strategy, and get rid of the convertible debt, then maybe they are worth a look. I suppose that is not much of a case for bulls but it is a potential best case scenario.